<DOC>
	<DOCNO>NCT00046995</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know schedule chemotherapy effective treating colon cancer . PURPOSE : Randomized phase III trial compare different schedule chemotherapy use carboplatin fluorouracil leucovorin treat patient stage IIB stage III colon cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Colon Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare disease-free survival patient completely resect stage IIB III colon cancer treat adjuvant chronomodulated vs standard schedule fluorouracil leucovorin calcium without carboplatin . - Compare overall survival patient treat regimen . - Compare toxicity regimens patient . - Compare quality life patient treat regimen . - Determine dose intensity fluorouracil carboplatin patient . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center disease stage ( IIB v III ) . Patients randomize 1 4 treatment arm . - Arm I ( standard schedule ) : Patients receive fluorouracil ( 5-FU ) IV continuously leucovorin calcium ( CF ) IV day 1 2 . - Arm II ( standard + carboplatin schedule ) : Patients receive 5-FU CF arm I plus carboplatin IV day 1 . - Arm III ( chronomodulated schedule ) : Patients receive 5-FU IV continuously CF IV continuously day 1-4 . - Arm IV ( chronomodulated + carboplatin schedule ) : Patients receive 5-FU CF arm III plus carboplatin IV continuously day 1-4 . Quality life assess . Treatment arm repeat every 14 day 9 course absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 660-800 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma colon Stage IIB III ( Dukes stage B2 C ) Complete curative resection perform within past 7 week ( negative margin ) No local regional relapse disease Tumor 15 cm anal margin Carcinoembryonic antigen le 5 ng/mL ( surgery ) No rectal cancer No metastatic disease PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 OR Karnofsky 60100 % Life expectancy Not specify Hematopoietic Neutrophil count least 2,000/mm3 Platelet count least 100,000/mm3 Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT SGPT great 5 time ULN Renal Creatinine great 1.5 time ULN Cardiovascular No serious coronary disease Other Not pregnant Fertile patient must use effective contraception No concurrent infectious disease No malignancy except adequately treat basal cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy No prior immunotherapy Chemotherapy No prior chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy ( surgery ) Surgery See Disease Characteristics Other No concurrent participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2002</verification_date>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>stage IIB colon cancer</keyword>
	<keyword>stage IIIA colon cancer</keyword>
	<keyword>stage IIIB colon cancer</keyword>
	<keyword>stage IIIC colon cancer</keyword>
</DOC>